ClinicalTrials.gg

Program

Warfarin

Also written as “warfarin”, “ZT002 injection, metformin, warfarin” and “Warfarin sodium”.

Its studies are mostly in Obesity · Venous Thrombosis · Diabetes Mellitus, Type 2 · Urinary Bladder, Overactive · Liver Cirrhosis, led by 4 companies.

Furthest: phase 4, since May 18, 200911 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca50 open or runningphase 1since May 18, 2009May 18, 2009none ahead
Boehringer Ingelheim40 open or runningphase 3since Dec 6, 2005Dec 6, 2005none ahead
Johnson & Johnson10 open or runningphase 1since Jul 21, 2011Jul 21, 2011none ahead
Kowa10 open or runningphase 4since Aug 9, 2010Aug 9, 2010none ahead

Also a collaborator on its studies: Eli Lilly, Bayer, Bristol-Myers Squibb and Valerio Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 6, 2005First study: phase 3 study in Atrial FibrillationNew to Boehringer IngelheimBoehringer Ingelheim · NCT00262600 · 18,113 enrolled · United States, Argentina, Australia and more
  2. May 18, 2009AstraZeneca's first study: phase 1 study in Diabetes Mellitus, Type 2New to AstraZenecaAstraZeneca · NCT00904176 · 30 enrolled · United States
  3. Apr 26, 2010Phase 1 study in HealthyBoehringer Ingelheim · NCT01111331 · 18 enrolled · Germany
  4. Aug 9, 2010Kowa's first study: phase 4 study in HealthyNew to KowaKowa · NCT01178853 · 48 enrolled · United States
  5. Sep 21, 2010Phase 1 study in PharmacokineticsAstraZeneca · NCT01214122 · Sweden
  6. Feb 21, 2011Phase 1 study in Arthritis, RheumatoidAstraZeneca · NCT01311622 · 15 enrolled · United Kingdom
  7. Jul 21, 2011Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT01400646 · 46 enrolled · Belgium
  8. Sep 8, 2011Phase 1 study in HypertriglyceridemiaAstraZeneca · NCT01431690 · 52 enrolled · United States
  9. Jan 20, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02345304 · Germany
  10. Sep 2, 2015Phase 1 study in HealthyAstraZeneca · NCT02540668 · 15 enrolled · United States
  11. Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741385 · 4 enrolled · Germany

TargetBeta

VKORC1 →read by rule
“Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor; Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor”ChEMBL 37, by rule

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05741385Liver Cirrhosis · Germany–CompletedBoehringer IngelheimAug 9, 20244
NCT02540668Healthy · United States1CompletedAstraZenecaJan 31, 201615
NCT02345304Healthy · Germany1WithdrawnBoehringer IngelheimApr 20150
NCT01431690Hypertriglyceridemia · United States1CompletedAstraZenecaOct 201152
NCT01400646Healthy · Belgium1CompletedJohnson & JohnsonMay 201246
NCT01311622Arthritis, Rheumatoid · United Kingdom1CompletedAstraZenecaMay 201115
NCT01214122Pharmacokinetics · Sweden1WithdrawnAstraZenecaDec 20100
NCT01178853Healthy · United States4CompletedKowaOct 201048
NCT01111331Healthy · Germany1CompletedBoehringer IngelheimJul 201018
NCT00904176Diabetes Mellitus, Type 2 · United States1CompletedAstraZenecaAug 200930
NCT00262600Atrial Fibrillation · United States, Argentina, Australia and more3CompletedBoehringer IngelheimApr 200918,113

How it is read

Names in the registry

  • “Warfarin”, 20 entries
  • “warfarin”, 7 entries
  • “ZT002 injection, metformin, warfarin”, 1 entry
  • “Warfarin sodium”, 1 entry
  • “Drug Cocktail”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.